ACADIA Pharmaceuticals Selected to Join New NASDAQ NeuroInsights Neurotech Index
Tuesday September 25, 9:00 am ET
SAN DIEGO--(BUSINESS WIRE)--ACADIA Pharmaceuticals Inc. (Nasdaq:ACAD - News), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today announced that it has been selected to be one of the inaugural companies in the new NASDAQ® NeuroInsights® Neurotech Index. The index launched today and is calculated on a price return basis (NASDAQ:NERV - News) and a total return basis (NASDAQ:NRVX - News).
The NASDAQ NeuroInsights Neurotech Index is the first index designed to track the performance of leading neurotechnology companies which are listed and actively traded on one of the three major U.S. stock exchanges. The NASDAQ NeuroInsights Neurotech Index includes companies engaged in researching, developing, manufacturing and marketing pharmaceuticals, biologics, medical devices and diagnostics for the brain and nervous system. In addition to meeting minimum market criteria, the 32 companies included in the index must be identified by NeuroInsights as significantly involved in the neurotechnology industry, which includes developing treatments and diagnostics for disorders like Alzheimer's, addiction, anxiety, depression, epilepsy, multiple sclerosis, obesity, pain, Parkinson's, schizophrenia, sensory disorders, sleep disorders, stroke, and traumatic brain injury.<snip>
======================================================================
FACTBOX: NASDAQ NeuroInsights Neurotech Index
Tue Sep 18, 2007 12:05pm EDT [Reuters]
The following are the companies included in the Nasdaq NeuroInsights Neurotech Index, (NASDAQ:NERV) (NASDAQ:NRVX) which will be launched on September 25
Nasdaq NeuroInsights Neurotech index Components
Company Ticker Mkt Cap Weight
Mln
Acadia Pharmaceuticals (ACAD.O: Quote, Profile, Research) 557 2.26%
Acorda Therapeutics (ACOR.O: Quote, Profile, Research) 472 2.17%
Alexza Pharmaceuticals (ALXA.O: Quote, Profile, Research) 272 1.08%
Alkermes Inc. (ALKS.O: Quote, Profile, Research) 1,679 4.00%
Arena Pharmaceuticals (ARNA.O: Quote, Profile, Research) 854 3.48%
Aspect Medical Systems (ASPM.O: Quote, Profile, Research) 204 1.04%
Biogen Idec Inc. (BIIB.O: Quote, Profile, Research) 18,940 8.00%
Biovail Corp. (BVF.TO: Quote, Profile, Research) 2,786 4.00%
Cephalon Inc. (CEPH.O: Quote, Profile, Research) 5,005 8.00%
Cyberonics Inc. (CYBX.O: Quote, Profile, Research) 381 1.71%
Cypress Bioscience (CYPB.O: Quote, Profile, Research) 501 2.11%
DURECT Corp. (DRRX.O: Quote, Profile, Research) 366 1.50%
Elan Corp. (ELN.I: Quote, Profile, Research) 9,439 8.00%
Endo Pharmaceuticals (ENDP.O: Quote, Profile, Research) 4,301 4.00%
Forest Laboratories (FRX.N: Quote, Profile, Research) 12,551 8.00%
Integra LifeSciences (IART.O: Quote, Profile, Research) 1,283 4.00%
Javelin Pharmaceuticals (JAV.A: Quote, Profile, Research) 274 1.10%
Medivation Inc. (MDVN.O: Quote, Profile, Research) 539 2.06%
Micrus Endovascular (MEND.O: Quote, Profile, Research) 354 1.55%
Natus Medical Inc. (BABY.O: Quote, Profile, Research) 332 1.48%
Neurocrine Biosciences (NBIX.O: Quote, Profile, Research) 402 1.61%
Neurogen Corp. (NRGN.O: Quote, Profile, Research) 192 0.88%
Northstar Neuroscience (NSTR.O: Quote, Profile, Research) 262 1.25%
Pain Therapeutics Inc. (PTIE.O: Quote, Profile, Research) 420 1.76%
Penwest Pharmaceuticals (PPCO.O: Quote, Profile, Research) 281 1.23%
Sepracor Inc. (SEPR.O: Quote, Profile, Research) 2,998 4.00%
Shire Plc (SHP.L: Quote, Profile, Research) 14,402 8.00%
Somanetics Corp. (SMTS.O: Quote, Profile, Research) 259 1.09%
Somaxon Pharmaceuticals (SOMX.O: Quote, Profile, Research) 205 0.96%
Valeant Pharmaceuticals (VRX.N: Quote, Profile, Research) 1,470 4.00%
Vanda Pharmaceuticals (VNDA.O: Quote, Profile, Research) 372 1.69%
XenoPort Inc. (XNPT.O: Quote, Profile, Research) 1,001 4.00%
Inclusion criteria:
**A minimum market capitalization of $200 million. **A minimum three-month average daily trading volume of 100,000 shares.
**a minimum closing price of $3.00.
The index will use a modified market capitalization-weighted methodology. |
